BCR signalling pathway and its crosstalk with adhesion in B-cell malignancies: Development of combinational targeted therapy
Školitel: Marek Mráz
Instituce: Masaryk University, Faculty of Science
Obor: Life Sciences - Bio-omics
O mém projektu
We aim to design novel combinatorial therapy for chronic lymphocytic leukaemia (CLL) based on ibrutinib, an inhibitor of B-Cell Receptor (BCR) signalling. Ibrutinib therapy leads to remission in most patients, but as single agent is incapable to prevent relapse. We will analyse gene expression (RNA-seq) of CLL cells before and during ibrutinib therapy and use these data to identify proteins that cells utilize to overcome inhibition of BCR signalling. Based on this, selected inhibitors will be tested in vitro/vivo to define synergistic combination(s) with curative potential.